Vicore Pharma Holding Logo

Vicore Pharma Holding

VICO | ST

Overview

Corporate Details

ISIN(s):
SE0007577895 (+1 more)
LEI:
549300KTNBPTZLF01130
Country:
Sweden
Address:
Postbox 14, 414 51 Göteborg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of disease-modifying therapies by targeting the angiotensin II type 2 (AT2) receptor. The company's strategy focuses on activating this receptor to stop and reverse disease pathology, primarily in severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF). Its lead drug candidate is buloxibutid (C21), a first-in-class, orally available small molecule AT2 receptor agonist (ATRAG) in clinical development. In addition to its drug pipeline, Vicore is developing Almee™, a cognitive behavioral therapy-based digital therapeutic designed to address the psychological impact of living with pulmonary fibrosis. Almee™ has received Breakthrough Device Designation from the U.S. FDA. The company utilizes its expertise in ATRAG chemistry and biology to expand its pipeline with new therapies for additional indications.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Vicore Pharma Holding. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-22 08:00
Interim Report
Swedish 2.2 MB
2025-08-22 08:00
Interim Report
English 2.2 MB
2025-06-30 09:00
Declaration of Voting Results & Voting Rights Announcements
Increase in number of shares and votes in Vicore Pharma
English 102.5 KB
2025-06-30 09:00
Declaration of Voting Results & Voting Rights Announcements
Ökning av antalet aktier och röster i Vicore Pharma
Swedish 107.6 KB
2025-05-06 16:25
Post-Annual General Meeting Information
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
English 110.7 KB
2025-05-06 16:25
Post-Annual General Meeting Information
Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)
Swedish 111.7 KB
2025-05-06 08:00
Quarterly Report
Swedish 15.3 MB
2025-05-06 08:00
Interim Report
English 14.5 MB
2025-03-26 08:30
Pre-Annual General Meeting Information
Kallelse till årsstämma i Vicore Pharma Holding AB (publ)
Swedish 152.7 KB
2025-03-26 08:30
Pre-Annual General Meeting Information
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
English 154.5 KB
2025-03-26 08:00
Annual Report
Swedish 44.4 MB
2025-03-26 08:00
Annual Report
English 43.4 MB
2025-02-27 08:00
Earnings Release
Swedish 6.4 MB
2025-02-27 08:00
Annual Report
English 7.9 MB
2024-10-31 09:00
Share Issue/Capital Change
Ökning av antalet aktier och röster i Vicore Pharma
Swedish 107.9 KB

Automate Your Workflow. Get a real-time feed of all Vicore Pharma Holding filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Vicore Pharma Holding via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-13 Ahmed Mousa Other Buy 11,034 90,920.16 SEK
2025-05-13 Ahmed Mousa Other Buy 757 6,230.11 SEK
2024-10-24 Johannes Schikan Other Other 355 2,485.00 SEK
2024-09-23 Ann Barbier Other Buy 42,500 298,775.00 SEK
2024-09-11 Ahmed Mousa Other Buy 32,000 248,169.60 SEK
2024-09-10 Ahmed Mousa Other Buy 95,000 752,248.00 SEK
2022-06-08 Jacob Uno Stanley Gunterberg Other Buy 6,400 220,800.00 SEK
2022-06-03 Johannes Schikan Other Buy 4,000 119,880.00 SEK
2022-06-03 Sara Malcus Other Buy 2,902 87,495.30 SEK
2022-06-01 Maarten Kraan Other Buy 4,025 121,152.50 SEK

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA